Hot Products

Moracin M
Catalog No: CFN92327

Moracin M is a phytoalexin. Moracin M inhibits PDE4D2, PDE4B2, PDE5A1, and PDE9A2 with the IC(50) values of 2.9, 4.5, >40, and >100 μM, respectively.

Moracin O
Catalog No: CFN96102

Moracin O shows significant neuroprotective, and analgesic activities, it also has a strong protective influence against doxorubicin-induced cardiomyopathy in H9c2 cells with the EC50 value of 4.5 ± 1.3 uM. Moracin O exhibits potent in vitro inhibitory activity against hypoxia-inducible factor (HIF-1), which is a key mediator during adaptation of cancer cells to tumour hypoxia.

Moracin P
Catalog No: CFN92324

Moracin P exhibits potent in vitro inhibitory activity against hypoxia-inducible factor (HIF-1), which is a key mediator during adaptation of cancer cells to tumour hypoxia. Moracin P might protect neuronal cell death against the oxidative stress induced by oxygen-glucose deprivation(OGD), can enhance cell viability in dose-dependent manner against OGD-induced cell death in neuroblastoma SH-SY5Y cells.

Moracin T
Catalog No: CFN92326

Moracin treatment can inhibit the double 12-O-tetradecanoylphorbol 13-acetate (TPA) treatment-induced morphological changes reflecting inflammatory response, including leucocyte infiltration, hyperplasia and cell proliferation; moracin treatment furthermore can significantly suppress the elevation in 4-HNE level and elevate expression of c-fos, c-myc and cycloxygenase-2 (COX-2) in normal epidermis induced by double application of TPA; the moracin may be protective influence in tumor promotion, utilization of Moracin may open a new avenue in the treatment of tumerigenesis.

Morellic acid
Catalog No: CFN92093

Morellic acid has anti-cancer activity, it strongly inhibited the migration of HUVEC at a low concentration of 0.5 μM in HUVEC cell migration assay in vitro. Morellic acid also has antiangiogenic activity.

Morin
Catalog No: CFN99929

Morin, a α-glucosidase inhibitor with an IC50 value of (4.48 ± 0.04) uM, it also exhibits inhibition in the generation of advanced glycation end products which was related to the long term complications of diabetes. Morin has anti-inflammatory and anti-oxidative effects by activating Nrf2 signal pathways and inhibiting NF-κB activation. it can be used to prevent bladder cancer, it prevents MMP-9 expression via the inhibition of transcription factors AP-1, Sp-1, and NF-κB.

Morindin
Catalog No: CFN70420

Reference standards.

Moringin
Catalog No: CFN89445

Moringin is a modulator of neuroinflammation via the β-catenin-PPARγ axis, it can activate Wnt canonical pathway by inhibiting GSK3β in a mouse model of experimental autoimmune encephalomyelitis. Moringin is effective in inducing apoptosis through p53 and Bax activation and Bcl-2 inhibition, it demonstrates the antitumor efficacy in human malignant astrocytoma cells. The combination of cannabidiol and moringin has anti-inflammatory, antioxidative, and anti-apoptotic effects.

Morolic acid
Catalog No: CFN89187

Morolic acid and moronic acid have shown sustained antidiabetic and antihyperglycemic action possibly mediated by an insulin sensitization with consequent changes of glucose, cholesterol and triglycerides, in part mediated by inhibition of 11β-HSD 1. Morolic acid exhibits pronounced radical scavenging activity against the stable 2,2-diphenyl-1-picrylhydrazyl radical and is a potent inhibitor of neutrophil elastase and cyclooxygenase-1 and -2 in vitro. Morolic acid has anti- inflammatory activity, it can inhibit leukotriene B4 production in rat polymorphonuclear leukocytes stimulated with calcium ionophore A 23187. Morolic acid exhibits promising anti-HIV activity, it also exhibits moderate inhibitory activity against glycogen phosphorylase.

Moronic acid
Catalog No: CFN97145

Moronic acid shows oral therapeutic efficacy in HSV-infected mice and possessed novel anti-HSV activity. It also shows significant anti-HIV activity (EC(50) 186) and was modified to develop more potent anti-AIDS agents. Moronic acid is a new structural lead for anti-EBV drug development, can substantially reduce the numbers of EBV particles produced by the cells after lytic induction. Morolic and moronic acids have shown sustained antidiabetic and antihyperglycemic action possibly mediated by an insulin sensitization with consequent changes of glucose, cholesterol and triglycerides, in part mediated by inhibition of 11β-HSD 1 as indicated by in vitro.